Natick, MA, United States of America

Timothy J Henderson

USPTO Granted Patents = 20 


 

Average Co-Inventor Count = 11.8

ph-index = 3

Forward Citations = 29(Granted Patents)


Location History:

  • Edison, NJ (US) (2013 - 2015)
  • New Providence, NJ (US) (2018)
  • Gainesville, FL (US) (2019)
  • Natick, MA (US) (2018 - 2024)

Company Filing History:


Years Active: 2013-2025

Loading Chart...
Loading Chart...
Loading Chart...
20 patents (USPTO):

Title: Innovator Spotlight: Timothy J. Henderson

Introduction

Timothy J. Henderson, located in Natick, MA, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 20 patents. His work focuses on developing innovative therapeutic solutions, particularly in cancer treatment.

Latest Patents

His latest patents include groundbreaking compounds that serve as small molecule inhibitors of the KRAS G12C mutant. The disclosure details compounds of Formula (I) or pharmaceutically acceptable salts that inhibit the G12C mutant of the Kirsten rat sarcoma (KRAS) protein. These compounds are expected to be utilized as therapeutic agents for cancer treatment. The disclosures also encompass pharmaceutical compositions that include these compounds and outline methods for their use in cancer therapy and prophylaxis.

Career Highlights

Timothy has held key positions in influential organizations such as Merck Sharp & Dohme Corporation and MSD R&D (China) Co., Ltd. His innovative contributions have played a pivotal role in advancing pharmaceutical research and development.

Collaborations

Throughout his career, Timothy has collaborated with esteemed colleagues, including Ryan D. Otte and Michael Man-Chu Lo. Together, they have contributed to the advancement of cutting-edge therapeutics, focusing on addressing complex health issues.

Conclusion

Timothy J. Henderson's work exemplifies the intersection of science and innovation, pushing the boundaries of therapeutic possibilities. With a strong record of patents and collaborations in renowned companies, he continues to be a driving force in the pharmaceutical industry, particularly in developing solutions for cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…